A modified release composition comprising 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
PK139970AUndetermined Publication Date: 2009-02-20SMITHKLINE BEECHAM CORP
0 Cites 0 Cited by
Patent Information
- Application Number
- PK199900959
- Authority / Receiving Office
- PK · PK
- Patent Type
- Applications
- Current Assignee / Owner
- Publication Date
- 2009-02-20
Abstract
A sustained release pharmaceutical composition comprising 2 to 12 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl) amino) ethoxy]benzyl]thiazoline-2, 4-dione or solvate thereof and a pharmaceutically acceptable carrier therefor, which dosage from provides a plasma concentration of 5-[4-[2-(N-methyl-N-(2-pyridyl) amino) ethoxy] benzyl]thiazoline-2, 4-dione of at least 50 ng / ml over a period of up to 24 hours.
Need to check novelty before this filing date? Find Prior Art
